HIV infection and immune activation: The role of coinfections

Current Opinion in HIV and AIDS

Volumn 11, Issue 2, 2016, Pages 191-200

  Boulougoura, Afroditi ^a   Sereti, Irini ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

biomarkers; immune reconstitution inflammatory syndrome; innate immunity; myeloid cells; tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER;

CRYPTOCOCCAL MENINGITIS; CYTOMEGALOVIRUS; FILOBASIDIELLA; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOMODULATION; META ANALYSIS (TOPIC); MIXED INFECTION; MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); T LYMPHOCYTE; TUBERCULOSIS; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INNATE IMMUNITY; PATHOPHYSIOLOGY;

BIOMARKERS; COINFECTION; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNITY, INNATE;

EID: 84957441441     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000241     Document Type: Review

References (90)

1. Zanoni BC, Gandhi RT. Update on opportunistic infections in the era of effective antiretroviral therapy. Infect Dis Clin North Am 2014; 28: 501-518.
2. Masur H, Brooks JT, Benson CA, et al., National Institutes of H, Centers for Disease C, Prevention, America HIVMAotIDSo. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58: 1308-1311.
3. Djawe K, Buchacz K, Hsu L, et al. Mortality risk after AIDS-defining opportunistic illness among HIV-infected persons-San Francisco. J Infect Dis 2015; 212: 1366-1375.
4. Masur H, Read SW. Opportunistic infections and mortality: still room for improvement. J Infect Dis 2015; 212: 1348-1350.
5. Masur H. HIV-related opportunistic infections are still relevant in 2015. Top Antivir Med 2015; 23: 116-119.
6. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382: 1525-1533.
7. Group ISS, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807.
8. IeDea, Collaborations ARTC. Avila D, Althoff KN, Mugglin C, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 2014; 65: e8-e16.
9. Bradley H, Hall HI, Wolitski RJ, et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV-United States.MMWRMorb Mortal Wkly Rep 2014; 63: 1113-1117.
10. Siedner MJ, Ng CK, Bassett IV, et al. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a metaanalysis. Clin Infect Dis 2015; 60: 1120-1127.
11. Mocroft A, Lundgren JD, Sabin ML, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013; 10: e1001510.
12. http://www.who.int/mediacentre/factsheets/fs104/en/Fact sheet N8104. Updated October 2015.
13. Phung BC, Sogni P, Launay O. Hepatitis B and human immunodeficiency virus co-infection. World J Gastroenterol 2014; 20: 17360-17367.
14. Melhem NM, Rahhal N, Charide R, et al. Human immunodeficiency virus and viral hepatitis among high-risk groups: understanding the knowledge gap in the Middle East and North Africa Region. World J Hepatol 2015; 7: 2619-2630.
15. Centers for Disease Control. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data: United States and 6 dependent areas -2013. Supplemental report, vol. 20. 2015. http://www.cdc.gov/hiv/library/reports/surveillance. [Accessed October 2015].
16. Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol 2014; 11: 362-371.
17. Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and preemptive treatment into routine HIV care. J Acquir Immune Defic Syndr 2012; 59: e85-e91.
18. Lichtner M, Cicconi P, Vita S, et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis 2015; 211: 178-186.
19. Schaftenaar E, Verjans GM, Getu S, et al. High seroprevalence of human herpesviruses in HIV-infected individuals attending primary healthcare facilities in rural South Africa. PLoS One 2014; 9: e99243.
20. Barnabas RV, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res 2012; 10: 228-237.
21. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009; 48: 101-107.
22. Sereti I, Rodger AJ, French MA. Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV AIDS 2010; 5: 504-510.
23. French MA, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cellmediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992; 6: 1293-1297.
24. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol 2012; 10: 150-156.
25. Chang CC, Sheikh V, Sereti I, French MA. Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment. Curr HIV/AIDS Rep 2014; 11: 223-232.
26. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resourcelimited settings. Lancet Infect Dis 2008; 8: 516-523.
27. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010; 10: 791-802.
28. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006; 20: F1-F7.
29. Mahnke YD, Greenwald JH, DerSimonian R, et al. Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 2012; 119: 3105-3112.
30. Meintjes G, Wilkinson KA, Rangaka MX, et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008; 178: 1083-1089.
31. Pean P, Nerrienet E, Madec Y, et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood 2012; 119: 3315-3320.
32. Haridas V, Pean P, Jasenosky LD, et al. TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIVinfected patients with TB. AIDS 2015; 29: 263-273.
33. Goovaerts O, Jennes W, Massinga-Loembe M, et al. Lower pre-treatment T cell activation in early- and late-onset tuberculosis-associated immune reconstitution inflammatory syndrome. PLoS One 2015; 10: e0133924.
34. Wilkinson KA, Walker NF, Meintjes G, et al. Cytotoxic mediators in paradoxical HIV-tuberculosis immune reconstitution inflammatory syndrome. J Immunol 2015; 194: 1748-1754.
35. Grant PM, Komarow L, Lederman MM, et al. Elevated interleukin 8 and Thelper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J Infect Dis 2012; 206: 1715-1723.
36. Tran HT, Van den Bergh R, Vu TN, et al. The role of monocytes in the development of tuberculosis-associated immune reconstitution inflammatory syndrome. Immunobiology 2014; 219: 37-44.
37. Tran HT, Van den Bergh R, Loembe MM, et al. Modulation of the complement system in monocytes contributes to tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2013; 27: 1725-1734.
38. Andrade BB, Singh A, Narendran G, et al. Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosisassociated immune reconstitution inflammatory syndrome. PLoS Pathog 2014; 10: e1004433.
39. Narendran G, Andrade BB, Porter BO, et al. Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS One 2013; 8: e63541.
40. Tan HY, Yong YK, Andrade BB, et al. Plasma interleukin-18 levels are a biomarker of innate immune responses that predict and characterize tuberculosis- associated immune reconstitution inflammatory syndrome. AIDS 2015; 29: 421-431.
41. Hsu DC, Faldetta KF, Pei L, et al. A paradoxical treatment for a paradoxical condition: infliximab use in three cases of mycobacterial IRIS. Clin Infect Dis 2015. doi: 10.1093/cid/civ841
42. Lai RP, Meintjes G, Wilkinson KA, et al. HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling. Nat Commun 2015; 6: 8451.
43. Torrado E, Fountain JJ, Liao M, et al. Interleukin 27R regulates CD4+ T cell phenotype and impacts protective immunity during Mycobacterium tuberculosis infection. J Exp Med 2015; 212: 1449-1463.
44. Pearl JE, Khader SA, Solache A, et al. IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice. J Immunol 2004; 173: 7490-7496.
45. Ravimohan S, Tamuhla N, Steenhoff AP, et al. Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and nonimmune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study. Lancet Infect Dis 2015; 15: 429-438.
46. Luetkemeyer AF, Kendall MA, Nyirenda M, et al. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr 2014; 65: 423-428.
47. Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Internal Med 2012; 157: 313-324.
48. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
49. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482-1491.
50. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365: 1471-1481.
51. Abay SM, Deribe K, Reda AA, et al. The effect of early initiation of antiretroviral therapy in TB/HIV coinfected patients: a systematic review and meta-analysis. J Int Assoc Provid AIDS Care 2015; 14: 560-570.
52. WHO Policy on Collaborative TB/HIV Activities: Guidelines for National Programmes and Other Stakeholders. 2012. WHO Guidelines Approved by the Guidelines Review Committee. Accessed October 2015. Available at: http://apps.who.int/iris/bitstream/10665/44789/1/9789241503006-eng.pdf?ua=1&ua=1.
53. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 2014; 370: 2487-2498.
54. Scriven JE, Rhein J, Hullsiek KH, et al. Early ART after cryptococcal meningitis is associated with cerebrospinal fluid pleocytosis and macrophage activation in a multisite randomized trial. J Infect Dis 2015; 212: 769-778.
55. Meya DB, Okurut S, Zziwa G, et al. Cellular immune activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome. J Infect Dis 2015; 211: 1597-1606.
56. Jarvis JN, Meintjes G, Bicanic T, et al. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. PLoS Pathog 2015; 11: e1004754.
57. Andrade BB, Hullsiek KH, Boulware DR, et al. Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis 2013; 207: 1379-1388.
58. Letang E, Lewis JJ, Bower M, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS 2013; 27: 1603-1613.
59. Gianella S, Redd AD, Grabowski MK, et al. Vaginal cytomegalovirus shedding before and after initiation of antiretroviral therapy in Rakai, Uganda. J Infect Dis 2015; 212: 899-903.
60. Faldetta KF, Kattakuzhy S, Wang HW, et al. Cytomegalovirus immune reconstitution inflammatory syndrome manifesting as acute appendicitis in an HIV-infected patient. BMC Infect Dis 2014; 14: 313.
61. Sheikh V, Caplan M, Wilson EM, et al. Cytomegalovirus immune reconstitution inflammatory syndrome manifesting as sialadenitis in an HIV-infected patient. AIDS 2013; 27: 1833-1835.
62. Tobian AA, Grabowski MK, Serwadda D, et al. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. J Infect Dis 2013; 208: 839-846.
63. Low AJ, Nagot N, Weiss HA, et al. Herpes simplex virus type-2 (HSV-2) cervico-vaginal shedding among women living with HIV-1 on antiretroviral therapy in Burkina Faso: an 8-year longitudinal study. J Infect Dis 2015. doi: 10.1093/infdis/jiv495.
64. Sierra-Madero JG, Ellenberg SS, Rassool MS, et al. Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial. Lancet HIV 2014; 1: e60-e67.
65. Sullivan ZA, Wong EB, Ndung'u T, et al. Latent and active tuberculosis infection increase immune activation in individuals co-infected with HIV. EBioMedicine 2015; 2: 334-340.
66. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20: 2275-2283.
67. Parrinello CM, Sinclair E, Landay AL, et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIVinfected women. J Infect Dis 2012; 205: 1788-1796.
68. Sacre K, Hunt PW, Hsue PY, et al. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. AIDS 2012; 26: 805-814.
69. Goulenok T, Boyd A, Larsen M, et al. Increased carotid intima-media thickness is not associated with T-cell activation nor with cytomegalovirus in HIVinfected never-smoker patients. AIDS 2015; 29: 287-293.
70. Effros RB. The silent war of CMV in aging and HIV infection. Mech Ageing Dev 2015. doi: 10.1016/j.mad.2015.09.003
71. Lee SA, Sinclair E, Hatano H, et al. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One 2014; 9: e89444.
72. Freeman ML, Mudd JC, Shive CL, et al. CD8 T-cell expansion and inflammation linked to CMV coinfection in ART-treated HIV infection. Clin Infect Dis 2015. doi: 10.1093/cid/civ840
73. Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203: 1474-1483.
74. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl JMed 2007; 356: 790-799.
75. Nagot N, Ouedraogo A, Konate I, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis 2008; 198: 241-249.
76. LeGoff J, Roques P, JenabianMA, et al. Variability of human immunodeficiency virus-1 in the female genital reservoir during genital reactivation of herpes simplex virus type 2. Clin Microbiol Infect 2015; 21: 873; e871-e879.
77. Reynolds SJ, Makumbi F, Newell K, et al. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis 2012; 12: 441-448.
78. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362: 427-439.
79. Redd AD, Newell K, Patel EU, et al. Decreased monocyte activation with daily acyclovir use in HIV-1/HSV-2 coinfected women. Sex Transm Infect 2015; 91: 485-488.
80. Yi TJ, Walmsley S, Szadkowski L, et al. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis 2013; 57: 1331-1338.
81. Masia M, Robledano C, Ortiz de la Tabla V, et al. Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients. PLoS One 2014; 9: e105442.
82. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979-1991.
83. Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS 2015; 10: 309-315.
84. Fernandez-Montero JV, Barreiro P, de Mendoza C, et al. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIVpositive patients. J Viral Hepat 2015. doi: 10.1111/jvh.12447.
85. McKibben RA, Haberlen SA, Post WS, et al. A cross-sectional study of the association between chronic hepatitis C virus infection and subclinical coronary atherosclerosis among participants in the multicenter AIDS cohort study. J Infect Dis 2015. doi: 10.1093/infdis/jiv396
86. Hodowanec AC, Lee RD, Brady KE, et al. A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection. BMC Infect Dis 2015; 15: 190.
87. Marquez M, Romero-Cores P, Montes-Oca M, et al. Immune activation response in chronic HIV-infected patients: influence of hepatitis C virus coinfection. PLoS One 2015; 10: e0119568.
88. Kushner LE, Wendelboe AM, Lazzeroni LC, et al. Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients. PLoS One 2013; 8: e60387.
89. Chew KW, Hua L, Bhattacharya D, et al. The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis 2014; 1: ofu104.
90. Tang L, Kottilil S. Treatment of hepatitis C in patients with HIV. Lancet HIV 2015; 2: e308-e309.